Cantor Fitzgerald Initiates Coverage on Esperion Therapeutics (NASDAQ:ESPR)

Cantor Fitzgerald began coverage on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report released on Tuesday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $8.00 price target on the biopharmaceutical company’s stock.

Several other brokerages have also issued reports on ESPR. Needham & Company LLC restated a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research report on Thursday, December 12th. Finally, StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $8.13.

Esperion Therapeutics Stock Performance

Shares of NASDAQ:ESPR opened at $2.46 on Tuesday. The stock’s 50-day simple moving average is $2.40 and its two-hundred day simple moving average is $2.22. The stock has a market capitalization of $484.71 million, a price-to-earnings ratio of -3.89 and a beta of 1.01. Esperion Therapeutics has a 52-week low of $1.58 and a 52-week high of $3.94.

Hedge Funds Weigh In On Esperion Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BOKF NA purchased a new stake in shares of Esperion Therapeutics in the second quarter worth about $26,000. Traphagen Investment Advisors LLC purchased a new stake in shares of Esperion Therapeutics during the 3rd quarter worth approximately $27,000. Xponance Inc. bought a new position in shares of Esperion Therapeutics during the 2nd quarter valued at approximately $28,000. National Bank of Canada FI grew its holdings in shares of Esperion Therapeutics by 115.9% in the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 10,225 shares in the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in Esperion Therapeutics in the second quarter worth $44,000. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.